Latest news with #ISC
Time of India
17 hours ago
- General
- Time of India
Edu challenges for visually impaired girl
1 2 3 4 5 6 In a freewheeling chat with TOI's Debasish Chatterjee, Nikita Kumari (18) talks about the challenges she is facing in her life and while pursuing her education. She said for special children, the road is full of thorns even after assurances of welfare from the govt You are a visually challenged student and passed the ISC in humanities from CISCE board this year. What are the challenges you are facing now? I want to pursue a course in journalism but educational institutes in Delhi and others are not ready to enrol a blind girl as they lack the basic infrastructure. I have scored 78% in ISC. My parents and I are trying hard since the results were out. All colleges, we have approached, have not given any positive response. You are one of the few visually challenged students who have appeared for CISCE and the first candidate from Jamshedpur. What was the board's reaction? Initially, even after my enrolment in Class 11 at Kerala Public School, Kadma, CISCE was not ready to allow my admission. It was because of the hard efforts of our school authorities, especially the principal, which bore fruit and I could appear for the exam. What hiccups did you face during the board exam? The board had to prepare a different set of question papers for me, which was sent through mail. On many days, they were delayed a bit. I had a lot of difficulty in finding a writer for the exams. My school helped me a lot in this regard, too. What do you expect from CISCE for visually challenged students, so that they don't face the same problems? As a blind student and when our PM Narendra Modi is actively supporting 'divyang' people, CISCE should first readily admit these students. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Live Comfortably: 60 m² Prefab Bungalow for Seniors in Odesa Pre Fabricated Homes | Search Ads Search Now Undo Next, all private schools should have proper infrastructure to support special children. Most importantly, CISCE should have the facility for visually challenged students to study in Braille and write exams, too, so that we are not dependent on any writer. You studied till Class 10 in Hindi medium. Why did you opt for the CISCE board in Class 11? I wanted to do my higher education in English, which is taught much better in CISCE than the state board. Many in my peer group asked me not to take this risk but I went ahead with my dreams and accepted the challenge. Switching over from Hindi medium to English, that too, for a blind student is a real uphill task. What do you look forward to after graduation? I will surely sit for the UPSC exam as I aspire to become an IAS or IPS officer. I can then actively help more 'divyang' students to complete higher education and get good jobs. From my childhood, I idolized former IPS officer Kiran Bedi and wanted to be like her. What other things have attracted you most, other than studying books? As a visually challenged sportsperson, I am a state-level cricket and football player. I have learnt karate. I have written more than 200 poems in Hindi. What are your expectations from society? I and my siblings were born a triplet and I am the only one who is visually impaired. Many pity me, which I don't like. Rather, I want people to be more aware of the plus points I have and discuss those.
Yahoo
6 days ago
- Business
- Yahoo
Enthera Pharmaceuticals Announces Publication in the Journal of Clinical Investigation Supporting the Clinical Development of Ebrasodebart
Preclinical data demonstrate crucial role of Transmembrane Protein 219 (TMEM219) in exacerbating inflammatory bowel disease (IBD) by inducing intestinal epithelial stem cell (ISC) death and impairing mucosal healing Findings support Phase 1 clinical development of Enthera's lead candidate, Ebrasodebart (Ent001), a monoclonal antibody targeting the IGFBP3/TMEM219 pathway Ebrasodebart is currently being studied in a proof-of-concept Phase 1b clinical trial for the treatment of ulcerative colitis (UC) MILAN, May 28, 2025--(BUSINESS WIRE)--Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing a first-in-class antibody therapeutic targeting the Insulin Growth Factor Binding Protein 3 (IGFBP3)/TMEM219 pathway for IBD and T1D, today announced the publication of preclinical data in The Journal of Clinical Investigation that revealed TMEM219's key role in driving ISC apoptosis and impairing mucosal healing in IBD. The findings support Enthera's clinical development of Ebrasodebart, a monoclonal antibody that targets the IGFBP3/TMEM219 pathway for the treatment of IBD, including UC and Crohn's disease. The company recently completed patient enrollment in the Phase 1b trial with Ebrasodebart in patients with UC. "Our publication in the prestigious Journal of Clinical Investigation is a validation of our scientific approach and testament to our team's commitment to targeting the TMEM219 pathway in IBD," said Dr. Lisa M. Olson, CEO of Enthera. "This research sheds light on the complex pathophysiology of IBD and supports the examination of the potential of Ebrasodebart to deliver clinical benefit to those patients who do not respond to existing immunomodulating treatments." As outlined in the publication, patients with refractory or active Crohn's disease experienced overactive TMEM219 signaling that correlated with a failure to regenerate the mucosal layer, despite immune suppressive therapy, and contributed to increased ISC death. Regulating TMEM219 by blocking the interaction between the protein and its ligand, IGFBP3, restored the self-renewal capabilities in vitro in patient-derived organoids (PDOs). These results were further supported by the demonstration of attenuating TMEM219 in vivo, which improved colitis symptoms and promoted mucosal healing in mouse models. The preclinical findings suggest the potential of a new therapeutic avenue focused on epithelial repair. About Enthera Pharmaceuticals Enthera Srl is a clinical-stage biotech company developing first-in-class antibody therapeutics to transform the treatment paradigm in inflammatory bowel diseases (IBD) and type 1 diabetes (T1D) by re-establishing stem cell capabilities. Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is dysregulated in IBD and T1D patients and leads to excessive apoptosis of stem cell in the gut and beta cells in the pancreas. Enthera's lead program, Ebrasodebart (Ent001), which is currently in Phase 1 clinical development, has the potential to restore the original intestinal mucosal structure in IBD and the endogenous pancreatic stem cell compartment in T1D, resulting in the restoration of organ function. Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof. Paolo Fiorina and Dr. Francesca D'Addio with BiovelocITA, Italy's first biotech accelerator. Enthera's discovery engine and assets are protected by a broad portfolio of patents. The company is backed by Sofinnova Partners, AbbVie Ventures, T1D Fund, Roche Venture Fund, and several Italian private investors. For further information: View source version on Contacts Enthera Pharmaceuticals Lisa M. Olson Ph.D., CEOinfo@ Trophic Communications Valeria Fisher or Veronika Máté+49 175 8041816 or +49 160 90816161enthera@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
6 days ago
- Business
- Time of India
Japan's reusable rocket startup ISC eyes US test launch in December
A Tokyo-based rocket startup said on Wednesday it will test-launch a prototype in the United States in December using an American engine, aiming to achieve the first U.S.-Japan joint commercial launch and address Japan's rocket shortage. The global race for commercial launch vehicles has been driven by SpaceX, which on Tuesday conducted a ninth test for its fully-reusable Starship. U.S. rivals including Blue Origin and companies in China and Europe also have reusable launcher plans. But Japan lacks cost-competitive launchers at home, which the government sees as a bottleneck in its efforts to double the domestic space industry's size to 8 trillion yen ($55.4 billion by the early 2030s. Innovative Space Carrier (ISC) said its ASCA 1.0 reusable launcher will conduct a 100-metre (109-yard) flight and landing test in Spaceport America in New Mexico, using a Hadley rocket engine from U.S.-manufacturer Ursa Major. Starting at a low altitude, ISC will repeat "ninja training-like" tests towards the goal of building an orbital launch vehicle by 2028 to cater to emerging Japanese satellite makers, ISC chief executive Kojiro Hatada told a press conference. Live Events "Japan's space industry needs its own space transportation there's no need to do everything ourselves to achieve it," he said at partner JFE Engineering's factory near Tokyo. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories Founded in 2022 by former government official Hatada, ISC has signed partnerships including with the British 3D printer firm WAAM3D to fast-track the launcher development. ISC has secured Japanese government's rocket development subsidies along with Space One and Toyota-backed Interstellar Technologies. It aims to lower the per-launch cost of a rocket capable of lifting a 100kg (220.46 lb) satellite to space to 500 million yen in the long run, Hatada said. Ursa Major's Hadley engine has been used by U.S. company Stratolaunch for hypersonic vehicle tests and been granted a U.S. export control permit so that it can be equipped on an ISC rocket. With ISC, "we look forward to continuing the partnership to further safe, cost-effective access to space," Ursa Major Chief Growth Officer Ben Nicholson said in an emailed statement.
Yahoo
6 days ago
- Business
- Yahoo
Japan's reusable rocket startup ISC eyes US test launch in December
By Kantaro Komiya YOKOHAMA (Reuters) -A Tokyo-based rocket startup said on Wednesday it will test-launch a prototype in the United States in December using an American engine, aiming to achieve the first U.S.-Japan joint commercial launch and address Japan's rocket shortage. The global race for commercial launch vehicles has been driven by SpaceX, which on Tuesday conducted a ninth test for its fully-reusable Starship. U.S. rivals including Blue Origin and companies in China and Europe also have reusable launcher plans. But Japan lacks cost-competitive launchers at home, which the government sees as a bottleneck in its efforts to double the domestic space industry's size to 8 trillion yen ($55.4 billion by the early 2030s. Innovative Space Carrier (ISC) said its ASCA 1.0 reusable launcher will conduct a 100-metre (109-yard) flight and landing test in Spaceport America in New Mexico, using a Hadley rocket engine from U.S.-manufacturer Ursa Major. Starting at a low altitude, ISC will repeat "ninja training-like" tests towards the goal of building an orbital launch vehicle by 2028 to cater to emerging Japanese satellite makers, ISC chief executive Kojiro Hatada told a press conference. "Japan's space industry needs its own space transportation there's no need to do everything ourselves to achieve it," he said at partner JFE Engineering's factory near Tokyo. Founded in 2022 by former government official Hatada, ISC has signed partnerships including with the British 3D printer firm WAAM3D to fast-track the launcher development. ISC has secured Japanese government's rocket development subsidies along with Space One and Toyota-backed Interstellar Technologies. It aims to lower the per-launch cost of a rocket capable of lifting a 100kg (220.46 lb) satellite to space to 500 million yen in the long run, Hatada said. Ursa Major's Hadley engine has been used by U.S. company Stratolaunch for hypersonic vehicle tests and been granted a U.S. export control permit so that it can be equipped on an ISC rocket. With ISC, "we look forward to continuing the partnership to further safe, cost-effective access to space," Ursa Major Chief Growth Officer Ben Nicholson said in an emailed statement. ($1 = 144.3400 yen)
Hindustan Times
27-05-2025
- General
- Hindustan Times
ICSE, ISC Re-Checking Result 2025 declared at cisce.org, direct link to check here
The Council for the Indian School Certificate Examinations has declared the ICSE, ISC Re-Checking Result 2025. Candidates who have registered for the re-checking of the answer sheets can check the results through the official website of CISCE at To check the re-checking results, candidates can follow the steps given below. 1. Visit the official website of CISCE at 2. Click on ICSE, ISC Re-Checking Result 2025 link available on the home page. 3. A new page will open where candidates will have to enter the login details. 4. Click on submit and your result will be displayed. 5. Check the result and download the page. 6. Keep a hard copy of the same for further need. The ICSE, ISC exam results were announced on April 30. The overall pass percentage for the ISC examination is 99.02%. A total of 99,551 candidates appeared for the ISC examination, out of which 98,578 students passed. The overall pass percentage of Class 12 for girls is 99.45%, and boys pass percentage is 98.64%. The Class 10 overall pass percentage is 99.09%. The girls pass percentage is 99.37% and boys pass percentage is 98.84%. For more related details candidates can check the official website of CISCE.
